Literature DB >> 3736301

Head and neck war injuries: 10-year experience at the American University of Beirut Medical Center.

G M Zaytoun, A H Shikhani, S D Salman.   

Abstract

Lebanon has witnessed over the past 10 years fierce outbreaks of violence resulting in heavy casualties. Head and neck injuries secondary to bullets, shrapnel, and/or glass were quite frequent: 1,357 injuries in 1,021 patients were taken care of by members of the Department of Otolaryngology between 1975 and 1984. They were distributed as follows: (Formula: see text). Fractures of the mandible were treated by closed reduction in 54% of cases and by open reduction in 46%; 74% healed well and 26% required secondary surgery. Primary repair of oral cavity injuries resulted in healing in 68% of cases; 32% had dehiscences or fistulae. In around one-third of the orbital injuries, the orbital contents herniated into the maxillary sinus, so orbital floor repairs had to be done with good results in 82% of cases. The nasal fractures were treated by closed reduction in 75% of cases and open reduction when the wound was open in the rest. The overall infection rate was 12%. The most common offending organisms were, in order of frequency, S. aureus, P. aeruginosa, and E. coli.

Entities:  

Mesh:

Year:  1986        PMID: 3736301

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  3 in total

1.  External laryngotracheal trauma.

Authors:  Davorin Danic; Drago Prgomet; Alen Sekelj; Krunoslav Jakovina; Ana Danic
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-10-05       Impact factor: 2.503

Review 2.  Penetrating injuries involving the anterior cranial fossa.

Authors:  M Roth; A D Kornblut; L M Spetka; D K Heffner
Journal:  Arch Otorhinolaryngol       Date:  1989

Review 3.  Microbiology and risk factors associated with war-related wound infections in the Middle East.

Authors:  Z T Sahli; A R Bizri; G S Abu-Sittah
Journal:  Epidemiol Infect       Date:  2016-03-02       Impact factor: 4.434

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.